There is a 14-story office building at 1 State Street, in the heart of Boston’s Financial District, that has been quietly emptying out for years. It sits one block from Faneuil Hall, two blocks from the waterfront, steps from three MBTA lines. By almost any measure, it is exactly where people should want to live. […]
Boston’s Empty Office Buildings Are Becoming Apartments. 1 State Street Is Next Read More »
There is a number buried in the Federal Reserve’s latest consumer survey that deserves more attention than it is getting. The share of American workers who expect to voluntarily quit their jobs in the next twelve months has just hit a record low — dropping to 15.9%, the lowest reading since the New York Fed
Fed Survey Shows a Frozen Labor Market — And Boston’s Startups Should Pay Attention Read More »
Every year, thousands of professionals make one of the most consequential financial decisions of their lives in Boston: whether to take a job offer, negotiate a raise, or make the leap from one sector to another. And every year, they navigate that decision with incomplete information — company-by-company data points, anecdotal comparisons from colleagues, and
Boston Salaries: What Tech, Finance, and Healthcare Actually Pay Read More »
Every year, LexisNexis publishes a list that the financial and scientific world tends to treat as a quiet but credible report card on global innovation. The Top 100 Global Innovators ranking does not measure press releases or funding rounds or how many times a CEO appeared on a podcast. It is built on something harder
Boston Places Five Companies on the World’s Most Exclusive Innovation List Read More »
In the high-stakes world of metabolic health, the next frontier isn’t a more effective injection—it’s a pill. As of late February 2026, two Boston-based startups, Vivtex and Nimbus Therapeutics, have emerged as the vanguard in the race to disrupt the $100 billion obesity market dominated by giants like Novo Nordisk and Eli Lilly. This week’s
